CD19 and acute lymphoblastic leukemia: Kymriah (tisagenlecleucel) was the first approved CD19 CAR-T therapy by the FDA for the treatment of relapsed/refractory pediatric and young adult B-cell acute lymphoblastic leukemia (ALL) in 2017 [36].